ACR Leaders at ECR 2026
ACR leaders showcased advances in radiology AI and global programs driving safe adoption, quality assurance and international collaboration.
Read moreACR Data Science Institute’s AI Central had a busy month, adding a new product to the Transparent-AI program and 12 products to the directory.
A new product was added to our Transparent-AI program, which is designed to increase transparency in imaging AI and help end users have better informed discussions and selection criteria when making decisions about which algorithm might be most appropriate for their local target population.
Visage Imaging Inc. joined the Transparent-AI program with their product Visage Breast Density. Visage Breast Density is a software application that assesses breast density from a mammography study and provides a density category A, B, C, or D according to the ACR BI-RADS Atlas 5th Edition to aid radiologists in the assessment of breast tissue composition.
Transparent-AI consists of voluntarily provided data elements solicited from participating imaging AI manufacturers who currently have an FDA-cleared product in the U.S. market. Manufacturers who participate in this program will receive the Transparent-AI badge on their product listing.
Our AI Central directory has also been updated with 12 new products. This information is pulled directly from FDA 510K documents and updated by ACR staff. With this latest update, we see many newly cleared FDA products designed for chest x-rays.
New products include:
FEops HEARTguideTM, FEops HEARTguideTM ALPACA
TruPlan Computed Tomography (CT) Imaging Software
Viz HDS, Viz Volume Plus, Viz ICH+
ACR Leaders at ECR 2026
ACR leaders showcased advances in radiology AI and global programs driving safe adoption, quality assurance and international collaboration.
Read moreACR Encourages Flexibility in HHS Information Blocking Rules
ACR urges HHS to maintain AI transparency rules and adopt a requestor‑preference exception to support patient‑directed access to health data.
Read moreACR Provides Policy Guidance to HHS on Clinical AI
ACR recommended stronger AI oversight, more research funding, and sustainable Medicare payment to support safe clinical AI adoption.
Read more